The global Argatroban market is valued at 84 million US$
Argatroban is a synthetic direct thrombin inhibitor and the chemical name is 1-[5- [(aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl]amino]pentyl]-4-methyl-2-piperidinecarboxylic acid, monohydrate. Argatroban has 4 asymmetric carbons. One of the asymmetric carbons has an R configuration (stereoisomer Type I) and an S configuration (stereoisomer Type II). Argatroban consists of a mixture of R and S stereoisomers at a ratio of approximately 65:35.
In the last several years, the global market of Argatroban Industry decreased with the average production growth rate about XX%.
The global capacity of Argatroban reduced to XX grams
from XX grams. It is predicted that the argatroban demand will continue to decrease with an average growth rate of XX% in the coming five years.
Japan is the still largest supplier of argatroban with the production market share of XX% and the consumer market share of XX%.
The price of argatroban is relatively expensive. The largest consumers have developed countries with high income. The USA occupied a market share of XX%. The second place in Europe, following North America with the consumer market share of XX%.
China has few companies entering the market with a production share of only XX%, and demand cannot be satisfied with supply. Large quantities of argatroban have to be imported.
Initially, compared with hirudin and heparin, the therapeutic dose has little effect on platelet, no antigen, and strong antithrombotic effect. The sale value has reached XX million USA dollars. But because of its narrow therapeutic area, uncertain factors on humans bodies and fierce competition from other substitutes, it sales far less than other thrombin inhibitors. The value reduced to XX million USA dollars.
The global Argatroban market is valued at 84 million US$ and will reach XX million US$ by the end of 2025, growing at a CAGR of XX% during 2018-2025.
Global Argatroban Market Professional Survey Report 2018 is a professional and in-depth study and available exclusively through Trusted Business Insights. Annual estimates and forecasts are provided for the period 2018 through 2025. Also, a five-year historic analysis is provided for these markets in this 94 pages report.
This market report provides in-depth analytics of the Argatroban industry including definition, classification, application and industry chain structure. The report focuses on global major leading industry players with information such as company profiles, product picture and specifications, sales, market share, and contact information.
Argatroban market report includes an in-depth analysis of the competitive landscape of this business vertical, constituting companies like:
Eagle Pharmaceuticals, Inc
Mitsubishi Tanabe Pharma
Teva Pharmaceutical Industries Ltd
Products Segmentation, this report displays the production, revenue, price, market share, and growth rate of each type as below:
By Industrial Application, the market can be split into:
Heparin-induced thrombocytopenia (HIT)
Percutaneous Coronary Intervention
Cerebral arterial thrombosis
Market Segment by Regions includes:
- North America (the USA, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, and Italy)
- Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)
- South America
- Middle East and Africa.